Overview

Price chart · mood · technical indicators

GRFS

Grifols SA ADRstock Healthcare

Drug Manufacturers - General

$8.2313.99%Current Market Mood:Bearish

Market Mood

Price Range (1Y)

$7.08$11.14

Current: $8.23

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

GRFS

+13.99%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio11.93Forward 9.25

EPS (TTM)$0.6943.5% YoY

Profit margin5.3%HEALTHCARE

Market cap$5.60BMid cap

Wall Street coverage

$11.10median target· current $7.02 (+58.1%)2 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 9.25
PEG ratio: 0.23
P/B: 0.91
P/S (TTM): 0.74
EV/EBITDA: 8.74

Profitability & growth

ROE (TTM): 6.2%
Operating margin: 17.5%
Revenue growth YoY: 0.3%
Dividend yield: 2.1%
Beta: 1.17

Last earnings

Apr 30, 2026 · Estimate $0.00 · Reported $0.00

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Grifols SA ADR

Company profile

Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: PARQUE EMPRESARIAL CAN SANT JOAN, BARCELONA, SPAIN
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$5.60B

Shares outstanding$680.6M

52W high$10.96

52W low$6.96

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

GRFS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Grifols S.A. Stock (ES0171996087): Q1 2026 Earnings Released Today

Grifols closes 29 plasma donation centers in US to optimise operations

Grifols (GRFS) to Release Earnings on Thursday

Grifols S.A. stock (ES0171996087): Is its plasma therapy dominance strong enough to unlock new upside?

Grifols, S.A. (GRFS) Stock Analysis: Exploring a 26.86% Upside Potential in the Healthcare Sector

Grifols S A : GigaGen presents positive phase 1 data on non-blocking anti-CTLA-4 drug candidate GIGA-564 at AACR 2026

Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers

Osborne Clarke advised Grifols S.A. on the conversion of Biotest AG into a GmbH & Co. KGaA.

CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2

Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package

Grifols SA stock (ES0171996087): Why does its plasma therapy model matter more now for U.S. investor

[6-K] Grifols SA Current Report (Foreign Issuer) | GRFS SEC Filing - Form 6-K

Grifols S.A. stock (ES0171996087): Why does its plasma leadership matter more now for U.S. investors

Grifols S A : successfully completes refinancing of 2027 maturities, further strengthening balance sheet and extending debt profile April 14 2026

Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors

Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors

GRFS PE Ratio & Valuation, Is GRFS Overvalued

Grifols facing restrictions in Canada after plasma donor deaths

Grifols’ Canadian License Restricted After Plasma Donor Deaths

Grifols S A : fully refinances all 2027 maturities following a significantly upsized €3bn Term Loan B

About Grifols SA ADR

Classification

Company profile

GRFS

Market Comparison

GRFS Market Analysis

Overview

GRFS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Grifols S.A. Stock (ES0171996087): Q1 2026 Earnings Released Today

Grifols closes 29 plasma donation centers in US to optimise operations

Grifols (GRFS) to Release Earnings on Thursday

Grifols S.A. stock (ES0171996087): Is its plasma therapy dominance strong enough to unlock new upside?

Grifols, S.A. (GRFS) Stock Analysis: Exploring a 26.86% Upside Potential in the Healthcare Sector

Grifols S A : GigaGen presents positive phase 1 data on non-blocking anti-CTLA-4 drug candidate GIGA-564 at AACR 2026

Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers

Osborne Clarke advised Grifols S.A. on the conversion of Biotest AG into a GmbH & Co. KGaA.

CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2

Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package

Grifols SA stock (ES0171996087): Why does its plasma therapy model matter more now for U.S. investor

[6-K] Grifols SA Current Report (Foreign Issuer) | GRFS SEC Filing - Form 6-K

Grifols S.A. stock (ES0171996087): Why does its plasma leadership matter more now for U.S. investors

Grifols S A : successfully completes refinancing of 2027 maturities, further strengthening balance sheet and extending debt profile April 14 2026

Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors

Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors

GRFS PE Ratio & Valuation, Is GRFS Overvalued

Grifols facing restrictions in Canada after plasma donor deaths

Grifols’ Canadian License Restricted After Plasma Donor Deaths

Grifols S A : fully refinances all 2027 maturities following a significantly upsized €3bn Term Loan B

About Grifols SA ADR

Classification

Company profile

GRFS

Market Comparison